Gene therapy startup Passage Bio nabs Janssen neuro lead as CMO

Philadelphia skyline
Philadelphia-based Passage Bio has raised more than $300 million in its first two funding rounds this year. (Bruce Emmerling/Pixabay)

Mere weeks after getting off a major $110 million series B round, well-funded Passage Bio has grabbed a new C-suite member on top of its cash haul.

The Philadelphia biotech has raided Janssen’s exec team, nabbing Gary Romano, M.D., Ph.D., as its chief medical officer. Romano comes off a six-year stint as the J&J biotech unit’s head of clinical development for neurodegenerative disease and the deputy leader of the neurodegenerative disease therapeutic area. Before this, he headed up Merck’s central nervous system unit.

“Gary … brings deep industry knowledge and drug development expertise that will be pivotal to Passage’s success as we move our lead programs into the clinic over the coming year,” said Dr. Stephen Squinto, co-founder and interim CEO at Passage Bio.

Virtual Roundtable

ASCO Explained: Expert predictions and takeaways from the world's biggest cancer meeting

Join FiercePharma for our ASCO pre- and post-show webinar series. We'll bring together a panel of experts to preview what to watch for at ASCO. Cancer experts will highlight closely watched data sets to be unveiled at the virtual meeting--and discuss how they could change prescribing patterns. Following the meeting, we’ll do a post-show wrap up to break down the biggest data that came out over the weekend, as well as the implications they could have for prescribers, patients and drugmakers.

“I am confident (his) expertise will aptly serve our mission to support patients suffering from rare monogenic CNS diseases, and I look forward to continuing to expand our team of esteemed leaders to support our rapid organizational growth.”

It’s a big get for a little startup, but fits within its impressive cash haul: That $110 million series B followed its $116 million series A earlier in the year.

And Squinto isn’t kidding about its rapidity, as the biotech plans to use the money under the guidance of its new CMO to move two gene therapies into the clinic in the first half of next year, hewing closely to the strategy it sketched out in its first raise back in February. Those programs target rare pediatric disease GM1 gangliosidosis and neurodegenerative disorder frontotemporal dementia.

Passage Bio also recently grabbed a new program in the form of a progressive nervous system condition Krabbe disease. Passage Bio expects to take that gene therapy into humans in the second half of 2020. If Passage Bio hits that target, it will have taken three assets into the clinic within two years of properly getting started as a company.

That rate of progress is underpinned by work at Passage Bio’s academic partners. The University of Pennsylvania’s Gene Therapy Program is doing IND-enabling work on the treatments. Once a program gets past that stage, Passage Bio will take over for clinical development and beyond.

Work is also underway to establish the infrastructure needed to support the expanding pipeline. In July, Passage Bio entered into an agreement with Paragon Gene Therapy to set up a dedicated production suite. The suite, which is due to start operating in the second half of 2020, will support Passage Bio as it works to meet clinical and potentially commercial demand for its gene therapies.

Suggested Articles

The FDA named more than two dozen coronavirus antibody tests that should be taken off the market weeks after the agency clamped down on tests.

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

The machine-learning programs scroll through data to detect hard-to-spot patterns. Yet few have been tested against standard procedures.